Valeant price target raised to $75 from $64 at Jefferies Jefferies says Valeant's 2012 guidance was even better than its optimistic forecasts, and finds the company's goal of being a top 15 Pharma company by the end of 2013 intriguing. The firm says the goal would equate to a $160 per share valuation. Jefferies raised its price target for Valeant shares and keeps a Buy rating on the stock.
Valeant and Progenics' Relistor eceives positive opinion from EMA Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.